ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $3.50.

A number of brokerages recently issued reports on ALXO. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd. Finally, Jefferies Financial Group began coverage on shares of ALX Oncology in a report on Thursday, November 13th. They set a “buy” rating and a $4.00 target price for the company.

ALX Oncology Price Performance

Shares of ALXO stock opened at $1.48 on Tuesday. The business’s fifty day moving average is $1.36 and its 200 day moving average is $1.24. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.13. The stock has a market cap of $80.25 million, a price-to-earnings ratio of -0.73 and a beta of 0.51. ALX Oncology has a twelve month low of $0.40 and a twelve month high of $2.27.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). Research analysts expect that ALX Oncology will post -2.76 EPS for the current fiscal year.

Institutional Investors Weigh In On ALX Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. purchased a new stake in shares of ALX Oncology in the third quarter worth $1,195,000. Two Sigma Investments LP boosted its stake in ALX Oncology by 26.9% in the 3rd quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after purchasing an additional 128,737 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in ALX Oncology during the 3rd quarter valued at about $66,000. Jane Street Group LLC purchased a new stake in ALX Oncology during the 2nd quarter valued at about $84,000. Finally, Acadian Asset Management LLC increased its stake in ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after purchasing an additional 186,883 shares in the last quarter. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.